Gilead Presents PURPOSE 2 Trial Data At HIVR4P Conference Showing Twice-Yearly Lenacapavir Reduced HIV Infections By 96% Among Cisgender Men And Gender-Diverse People
Portfolio Pulse from Benzinga Newsdesk
Gilead Sciences presented data from the PURPOSE 2 trial at the HIVR4P conference, showing that its drug Lenacapavir reduced HIV infections by 96% among cisgender men and gender-diverse people. Gilead plans to file for regulatory approval for Lenacapavir as PrEP by the end of 2024 and aims to expand access in high-incidence, resource-limited countries.
October 07, 2024 | 3:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Gilead's Lenacapavir demonstrated a 96% reduction in HIV infections in a recent trial. The company plans regulatory filings by the end of 2024 and aims to expand access in high-incidence, resource-limited countries.
The trial results showing a 96% reduction in HIV infections are highly positive, indicating potential for significant market impact. Regulatory filings and plans to expand access could enhance Gilead's market position and revenue potential.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100